Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12‐year population‐based cohort study

Abstract

Objective: To determine the risk for adverse pregnancy and fetal outcomes in intrahepatic cholestasis of pregnancy (ICP). Design: Population‐based cohort study. Setting: S wedish Medical Birth Register (MBR) 1997–2009. Population: A total of 1 213 668 singleton deliveries. Methods: Linkage of H ospital D ischarge R egister for exposure (ICP; n = 5477) with MBR for covariates. Main outcome measures: Gestational diabetes, pre‐eclampsia, prematurity, and stillbirth. Results: Intrahepatic cholestasis (ICP) was diagnosed in 0.32–0.58% of all pregnancies, with an increasing trend until 2005 (P < 0.0001). Compared with women who did not have ICP, women with ICP were more likely to have gestational diabetes (adjusted odds ratio, a OR, 2.81; 95% CI 2.32–3.41) and pre‐eclampsia (a OR 2.62, 95% CI 2.32–2.78). Women with ICP were also more likely to have spontaneous (a OR 1.60, 95% CI 1.47–1.93) and iatrogenic (a OR 5.95, 95% CI 5.23–6.60) preterm delivery, with increased rates of induction of labour (a OR 11.76, 95% CI 11.04–11.62). However, this actively managed cohort of ICP cases was not at increased risk of stillbirth (a OR 0.92, 95% CI 0.52–1.62). Infants in ICP deliveries were more likely to have a low (<7) 5‐minute A pgar score (a OR 1.45, 95% CI 1.14–1.85) and be large for gestational age at birth (a OR 2.27, 95% CI 2.02–2.55). Conclusions: Over time, a greater proportion of S wedish pregnant women have received a diagnosis of ICP, probably because of an increased awareness of the disorder. Our data confirm an increased risk of preterm delivery, but not of stillbirth, in actively managed ICP. The high rates of gestational diabetes and pre‐eclampsia are new findings, and need to be considered in the management of ICP pregnancies.